News | December 04, 2014

Chesapeake Urology Improves Prostate Cancer Detection and Diagnosis With 3-D Ultrasound/MRI Fusion Biopsy

More than 500 prostate biopsies have been performed utilizing this technology

biopsy systems, prostate, 3-d technology

December 4, 2014 — Chesapeake Urology Associates offers a state-of-the-art prostate cancer diagnostic, which fuses detailed MRI scans with live, real-time ultrasound images of the prostate. This biopsy system provides Chesapeake urologists with the capability to pinpoint tumors within the prostate gland, leading to more targeted treatment planning and better outcomes.

By combining advanced MRI imaging with 3-D ultrasound technology, this new biopsy system:

  • Creates a 3-D map of the prostate
  • Identifies suspicious lesions or targets on MRI
  • Fuses or overlaps the 3-D MRI image onto the real-time 3-D ultrasound image of the prostate
  • Provides clear visualization of the biopsy needle and the targeted lesion for accurate guidance
  • Stores the exact location of each biopsy sample for future referencebopsy

 

Unlike the standard 2-D TRUS-guided prostate biopsy, which takes random tissue samples from the prostate and has a higher rate of missing cancerous cells within the gland, the 3-D Ultrasound/MRI Fusion Biopsy combines the clarity of an MRI image with a 3-D ultrasound image. This creates an enhanced 3-D map of the prostate for improved visualization of the gland, allowing determination of the exact location of potential tumors.

For more information: www.chesapeakeurology.com

Related Content

Hypofractionated Radiation Provides Same Prostate Cancer Outcomes as Conventional Radiation
News | Intensity Modulated Radiation Therapy (IMRT) | October 31, 2018
An analysis led by researchers at Philadelphia’s Fox Chase Cancer Center found treating localized prostate cancer with...
Prostate Brachytherapy Shows Low Incidence of Short-Term Complications
News | Brachytherapy Systems | October 31, 2018
A new analysis of nearly 600 men receiving brachytherapy for prostate cancer shows overall procedure-related...
Biomarker blood test accurately confirms remission in non-smoker with HPV-associated oral cancer. ASTRO 2018 #ASTRO2018 #ASTRO #ASTRO18

Biomarker blood test accurately confirms remission in non-smoker with HPV-associated oral cancer.

News | Radiation Oncology | October 30, 2018
October 30, 2018 — A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to
Prostate Radiotherapy Outcomes Better for African-Americans Than Caucasian Patients according to a study presented at ASTRO 2018. #ASTRO #ASTRO18 #ASTRO2018
Feature | Prostate Cancer | October 30, 2018
October 30, 2018 — While popular beliefs and population data suggest that African-American men are at higher risk of
Combined Therapy Including Pelvic Lymph Node Radiation Provides Significant Benefit for Prostate Cancer Patients - late breaking study presented at ASTRO 2018.
News | Prostate Cancer | October 22, 2018
The first report of a large, international clinical trial shows that, for men who show signs of...
Boston Scientific Closes Acquisition of Augmenix Inc.
News | Prostate Cancer | October 17, 2018
Boston Scientific Corp. announced the close of its acquisition of Augmenix Inc., developer of the SpaceOAR Hydrogel...
New Guideline for Prostate Cancer Supports Shortened Radiation Therapy
News | Prostate Cancer | October 12, 2018
Three prominent medical societies issued a new clinical guideline for physicians treating men with early-stage prostate...
Leica Biosystems Launches MammoPort Specimen Containment and Transport System
Technology | Breast Biopsy Systems | October 03, 2018
Leica Biosystems announced the U.S. launch of MammoPort, the first integrated specimen containment and transport system...
CyberKnife System Provides Excellent Prostate Cancer Survival Rates in Five or Fewer Sessions
News | Stereotactic Body Radiation Therapy (SBRT) | September 27, 2018
Accuray Inc. announced that published data from two prospective, multi-center studies using differing protocols provide...